119 related articles for article (PubMed ID: 37852159)
21. Effects of time-of-day of hypertension treatment on ambulatory blood pressure and clinical characteristics of patients with type 2 diabetes.
Moyá A; Crespo JJ; Ayala DE; Ríos MT; Pousa L; Callejas PA; Salgado JL; Mojón A; Fernández JR; Hermida RC;
Chronobiol Int; 2013 Mar; 30(1-2):116-31. PubMed ID: 23181613
[TBL] [Abstract][Full Text] [Related]
22. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
23. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
Bramlage P; Pittrow D; Kirch W
Curr Med Res Opin; 2004 Oct; 20(10):1625-31. PubMed ID: 15462695
[TBL] [Abstract][Full Text] [Related]
24. Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya.
Kimando MW; Otieno FCF; Ogola EN; Mutai K
BMC Endocr Disord; 2017 Dec; 17(1):73. PubMed ID: 29191193
[TBL] [Abstract][Full Text] [Related]
25. Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study.
Kaasenbrood L; Poulter NR; Sever PS; Colhoun HM; Livingstone SJ; Boekholdt SM; Pressel SL; Davis BR; van der Graaf Y; Visseren FL;
Circ Cardiovasc Qual Outcomes; 2016 May; 9(3):213-21. PubMed ID: 27174798
[TBL] [Abstract][Full Text] [Related]
26. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Mann J; Julius S
Blood Press; 1998 May; 7(3):176-83. PubMed ID: 9758088
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed Type 2 diabetes: results from a United Kingdom study.
Guzder RN; Gatling W; Mullee MA; Mehta RL; Byrne CD
Diabet Med; 2005 May; 22(5):554-62. PubMed ID: 15842509
[TBL] [Abstract][Full Text] [Related]
28. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Kones R
Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
[TBL] [Abstract][Full Text] [Related]
29. Assessing 10-Year Cardiovascular Disease Risk in Malaysians With Type 2 Diabetes Mellitus: Framingham Cardiovascular Versus United Kingdom Prospective Diabetes Study Equations.
Yew SQ; Chia YC; Theodorakis M
Asia Pac J Public Health; 2019 Oct; 31(7):622-632. PubMed ID: 31535566
[TBL] [Abstract][Full Text] [Related]
30. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study.
Davis WA; Colagiuri S; Davis TM
Med J Aust; 2009 Feb; 190(4):180-4. PubMed ID: 19220181
[TBL] [Abstract][Full Text] [Related]
31. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus.
Berkelmans GFN; Gudbjörnsdottir S; Visseren FLJ; Wild SH; Franzen S; Chalmers J; Davis BR; Poulter NR; Spijkerman AM; Woodward M; Pressel SL; Gupta AK; van der Schouw YT; Svensson AM; van der Graaf Y; Read SH; Eliasson B; Dorresteijn JAN
Eur Heart J; 2019 Sep; 40(34):2899-2906. PubMed ID: 30629157
[TBL] [Abstract][Full Text] [Related]
32. Effect of bariatric surgery versus medical therapy on long-term cardiovascular risk in low BMI Chinese patients with type 2 diabetes: a propensity score-matched analysis.
Ke Z; Zhou X; Sun F; Li F; Tong W; Zhu Z
Surg Obes Relat Dis; 2022 Apr; 18(4):475-483. PubMed ID: 34969592
[TBL] [Abstract][Full Text] [Related]
33. Comparison of different vascular risk engines in the identification of type 2 diabetes patients with high cardiovascular risk.
Rodriguez-Poncelas A; Coll-de-Tuero G; Saez M; Garrido-Martín JM; Millaruelo-Trillo JM; Barrot de-la-Puente J; Franch-Nadal J;
BMC Cardiovasc Disord; 2015 Oct; 15():121. PubMed ID: 26464076
[TBL] [Abstract][Full Text] [Related]
34. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
[TBL] [Abstract][Full Text] [Related]
35. Adding pharmacists to primary care teams reduces predicted long-term risk of cardiovascular events in type 2 diabetic patients without established cardiovascular disease: results from a randomized trial.
Ladhani NN; Majumdar SR; Johnson JA; Tsuyuki RT; Lewanczuk RZ; Spooner R; Simpson SH
Diabet Med; 2012 Nov; 29(11):1433-9. PubMed ID: 22486226
[TBL] [Abstract][Full Text] [Related]
36. Blood Pressure Management in Adults With Type 2 Diabetes: Insights From the Diabetes Mellitus Status in Canada (DM-SCAN) Survey.
Grenier J; Goodman SG; Leiter LA; Langer A; Teoh H; Bhatt DL; Cheng AYY; Tan MK; Ransom T; Connelly KA; Yan AT
Can J Diabetes; 2018 Apr; 42(2):130-137. PubMed ID: 28552652
[TBL] [Abstract][Full Text] [Related]
37. WITHDRAWN: Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus.
Fuller J; Stevens LK; Chaturvedi N; Holloway JF
Cochrane Database Syst Rev; 2007 Jul; (4):CD002188. PubMed ID: 17636699
[TBL] [Abstract][Full Text] [Related]
38. [Cardiovascular risk profile in 40-year old men and 50-year old women in the Czech Republic: results of a cross-sectional survey].
Vrablík M; Chmelík Z; Lánská V
Vnitr Lek; 2014 Nov; 60(11):991-7. PubMed ID: 25600047
[TBL] [Abstract][Full Text] [Related]
39. Metabolic control and cardiovascular risk factors in type 2 diabetes mellitus patients according to diabetes duration.
Franch-Nadal J; Roura-Olmeda P; Benito-Badorrey B; Rodriguez-Poncelas A; Coll-de-Tuero G; Mata-Cases M;
Fam Pract; 2015 Feb; 32(1):27-34. PubMed ID: 25194144
[TBL] [Abstract][Full Text] [Related]
40. Recalculation of cardiovascular risk score as a surrogate marker of change in clinical care of diabetes patients: the Alphabet POEM project (Practice Of Evidence-based Medicine).
Lee JD; Morrissey JR; Patel V;
Curr Med Res Opin; 2004 May; 20(5):765-72. PubMed ID: 15140344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
